Vitiligo has long been regarded as a disease of the skin alone, a condition in which the immune system mistakenly destroys melanocytes, the pigment-producing cells that give skin its color. But a new systematic review published in the Archives of Dermatological Research suggests that the disorder may be far more than a cosmetic concern. Drawing together 33 studies encompassing 4,286 patients with vitiligo, researchers from Nicolaus Copernicus University in Torun, Poland, found that people with vitiligo face roughly double the risk of metabolic syndrome and insulin resistance compared with healthy individuals. The findings, synthesized according to the PRISMA reporting guidelines, add vitiligo to a growing list of autoimmune skin diseases, including psoriasis, that carry systemic cardiometabolic consequences.
The review, led by Barbara Kamińska together with Aleksandra Białczyk and Rafał Czajkowski, systematically searched PubMed and Web of Science from database inception through April 16, 2025, without language or date restrictions. After screening 1,264 initially identified records, the team retained 33 original observational studies, 12 cross-sectional and 21 case-control investigations, published between 2011 and 2024. Sample sizes ranged from 30 to 896 participants. Geographically, the evidence base was heavily skewed: 26 studies came from Asia, five from Europe, and only two from the Americas, a concentration the authors flag as a potential limitation for generalizability.
The headline numbers are striking. Among the 17 studies that reported the prevalence of metabolic syndrome, a cluster of risk factors including central obesity, elevated blood pressure, impaired glucose metabolism, and dyslipidemia, 505 of 1,473 patients with vitiligo, or 34.3 percent, met diagnostic criteria, most commonly those set by the NCEP ATP III guidelines. In control groups, by contrast, only 240 of 1,289 participants, or 18.6 percent, qualified. Thirteen of the 15 studies providing comparative data found higher rates of metabolic syndrome in the vitiligo groups. Individual study estimates varied widely, from 6.7 percent to 50.7 percent, a spread the authors attribute to differing diagnostic thresholds, patient selection, and regional metabolic backgrounds.
Insulin resistance, the reduced ability of cells to respond to normal circulating levels of insulin, told a similar story. The most widely used proxy, the Homeostasis Model Assessment of Insulin Resistance, or HOMA-IR, is calculated as fasting plasma insulin multiplied by fasting plasma glucose and divided by 22.5. Across seven studies that applied HOMA-IR cut-off values, insulin resistance was identified in 279 of 494 patients with vitiligo, or 56.5 percent, versus 125 of 380 controls, or 32.9 percent. In every one of the six comparative studies, the prevalence was higher in the vitiligo group. Reported rates among patients ranged from 26.7 percent to 88.7 percent, and one study that excluded people with diabetes still found insulin resistance in 63 percent of its vitiligo cohort.
Supporting biochemical data reinforced the pattern. Across ten studies, mean fasting glucose in vitiligo patients averaged 95.66 mg/dL compared with 78.5 mg/dL in controls, while mean fasting insulin averaged 12.96 µIU/mL against 9.01 µIU/mL in control participants. Lipid abnormalities also appeared repeatedly: decreased HDL cholesterol, elevated LDL-to-HDL ratios, and increased triglycerides were frequently documented. Some studies reported higher insulin and C-peptide levels even in non-diabetic patients, hinting at early metabolic dysregulation, although at least one investigation observed a more favorable lipid profile in vitiligo patients, underscoring the inconsistency across the literature.
Whether these metabolic changes track with the severity or duration of vitiligo remains contested. Several studies found that active disease, greater body surface area involvement, and higher scores on the Vitiligo Area Scoring Index or the Vitiligo Disease Activity score predicted metabolic syndrome, insulin resistance, or elevated levels of inflammatory and metabolic biomarkers such as FABP4, VAP-1, and YKL-40. Disease severity has also been identified as an independent predictor of metabolic syndrome and subclinical atherosclerosis, and one study reported a strong correlation between serum homocysteine and VASI scores. Yet other investigations found no relationship between severity measures and metabolic indicators, and the evidence on disease duration is similarly divided, with some studies linking longer duration to metabolic risk and one even finding metabolic syndrome more common in patients with shorter disease duration, possibly reflecting higher disease activity early in its course.
The biological plausibility of a skin-metabolism connection rests on shared mechanisms of oxidative stress, chronic inflammation, and mitochondrial dysfunction. Reactive oxygen species are believed to sensitize melanocytes to immune-mediated destruction in vitiligo, and the same redox imbalance promotes serine phosphorylation of insulin receptors, disrupting insulin signaling and impairing glucose metabolism. Proinflammatory cytokines, including interleukin-1, interleukin-6, and tumor necrosis factor-alpha, are elevated in both conditions and further amplify the pro-oxidative state. Melanocytes resident in adipose tissue normally exert anti-inflammatory effects and reduce reactive oxygen species; their loss may contribute to increased oxidative stress and lipid peroxidation throughout the body.
Recent work has pushed this mechanistic story to the cellular level. Keratinocytes, melanocytes, and fibroblasts all express functional insulin and insulin-like growth factor 1 receptors, implicating insulin-dependent signaling in skin homeostasis. Experimental data show that IGF-1 can reduce oxidative damage and inflammatory cytokine production in skin models, while clinical studies report decreased serum IGF-1 levels in patients with vitiligo. Most provocatively, a 2025 study by Caputo and colleagues provided the first direct evidence of insulin resistance in keratinocytes and melanocytes derived from vitiligo patients, demonstrating impaired mitochondrial ATP production and altered cellular energy sensing despite normal extracellular glucose levels. This suggests that intrinsic mitochondrial dysfunction may underlie both the cutaneous and systemic metabolic features of the disease, opening potential avenues for therapies aimed at metabolic reprogramming.
The authors are careful about what the evidence can and cannot show. Because of considerable heterogeneity in study designs, diagnostic criteria for metabolic syndrome, and HOMA-IR thresholds, which ranged from greater than 1.93 to greater than 2.9 across studies, a quantitative meta-analysis was not feasible, and the findings were synthesized narratively. Most included studies were cross-sectional and focused on disease presence rather than progression, so causal relationships remain uncertain. Methodological quality was assessed with the Newcastle-Ottawa Scale by two independent reviewers, with a third resolving disagreements. The reviewers also note that most studies did not specify whether individuals with diabetes were excluded or analyzed separately, complicating interpretation of some glucose data, and that the geographic concentration of studies in Asia and the Middle East may limit how broadly the conclusions apply.
Even with those caveats, the practical message for clinicians is clear. The review argues that metabolic screening deserves consideration in patients with vitiligo, particularly those with active, extensive, or long-standing disease, much as it is now routine for patients with severe psoriasis. If future prospective, multicenter studies with standardized definitions confirm the association, and clarify whether metabolic disturbances play a causal role in vitiligo pathogenesis or progression, targeted metabolic interventions might one day improve outcomes for a disease currently treated almost exclusively as a disorder of pigmentation. For the millions of people living with vitiligo worldwide, the skin may finally be recognized as a window into the body’s deeper metabolic health.
Subject of Research: Association between vitiligo and cardiometabolic risk, specifically insulin resistance and metabolic syndrome
Article Title: Insulin resistance and metabolic syndrome in patients with vitiligo: a systematic review and narrative synthesis
Article References: Kamińska, B., Białczyk, A., & Czajkowski, R. (2026). Insulin resistance and metabolic syndrome in patients with vitiligo: a systematic review and narrative synthesis. Archives of Dermatological Research, 318(1), Article 455. https://doi.org/10.1007/s00403-026-04909-9
Image Credits: AI Generated
DOI: 10.1007/s00403-026-04909-9
Keywords: vitiligo, metabolic syndrome, insulin resistance, HOMA-IR, melanocytes, oxidative stress, autoimmune disease, cardiometabolic risk, systematic review, inflammation, IGF-1, dermatology
News Source: Ophelia Keating. (October 6, 2026). Skin Deep No More: Vitiligo Doubles the Risk of Metabolic Syndrome and Insulin Resistance. Scienmag.
